Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Retina Consultants of Southern Colorado PC; Clinical Research Department
mi
from
Colorado Springs, CO
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Retina Consultants of Southern Colorado PC; Clinical Research Department
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Colorado Retina Associates
mi
from
Golden, CO
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Colorado Retina Associates
mi
from
Golden, CO
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Rand Eye
mi
from
Deerfield Beach, FL
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Rand Eye
mi
from
Deerfield Beach, FL
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
National Ophthalmic Research Institute
mi
from
Fort Myers, FL
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
National Ophthalmic Research Institute
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Florida Eye Associates
mi
from
Melbourne, FL
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Florida Eye Associates
mi
from
Melbourne, FL
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Southern Vitreoretinal Assoc
mi
from
Tallahassee, FL
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Southern Vitreoretinal Assoc
mi
from
Tallahassee, FL
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Southeast Retina Center, P.C.
mi
from
Augusta, GA
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Southeast Retina Center, P.C.
mi
from
Augusta, GA
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Midwest Eye Institute
mi
from
Indianapolis, IN
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Midwest Eye Institute
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Wolfe Eye Clinic
mi
from
West Des Moines, IA
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Wolfe Eye Clinic
mi
from
West Des Moines, IA
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
The Retina Care Center
mi
from
Baltimore, MD
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
The Retina Care Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Vitreo Retinal Surgery
mi
from
Minneapolis, MN
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Vitreo Retinal Surgery
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Sierra Eye Associates
mi
from
Reno, NV
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Sierra Eye Associates
mi
from
Reno, NV
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Eye Associates of New Mexico
mi
from
Albuquerque, NM
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Eye Associates of New Mexico
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Vitreoretinal Consultants
mi
from
Great Neck, NY
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Vitreoretinal Consultants
mi
from
Great Neck, NY
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Opthalmic Consultants of LI
mi
from
Lynbrook, NY
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Opthalmic Consultants of LI
mi
from
Lynbrook, NY
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Char Eye Ear &Throat Assoc
mi
from
Charlotte, NC
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Char Eye Ear &Throat Assoc
mi
from
Charlotte, NC
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Retina Assoc. of Cleveland
mi
from
Cleveland, OH
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Retina Assoc. of Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Oregon Retina, LLP
mi
from
Eugene, OR
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Oregon Retina, LLP
mi
from
Eugene, OR
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Retina Northwest, PC
mi
from
Portland, OR
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Retina Northwest, PC
mi
from
Portland, OR
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Charles Retina Institution
mi
from
Germantown, TN
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Charles Retina Institution
mi
from
Germantown, TN
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Texas Retina Associates
mi
from
Arlington, TX
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Texas Retina Associates
mi
from
Arlington, TX
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Austin Retina Associates
mi
from
Austin, TX
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Austin Retina Associates
mi
from
Austin, TX
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Retina Research Center
mi
from
Austin, TX
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Retina Research Center
mi
from
Austin, TX
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Retina Associates of Utah
mi
from
Salt Lake City, UT
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Retina Associates of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Retina Vitreous Assoc of FL
mi
from
Saint Petersburg, FL
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Retina Vitreous Assoc of FL
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Southeastern Retina Associates Chattanooga
mi
from
Chattanooga, TN
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Southeastern Retina Associates Chattanooga
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Retina Res Institute of Texas
mi
from
Abilene, TX
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Retina Res Institute of Texas
mi
from
Abilene, TX
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Strategic Clinical Research Group, LLC
mi
from
Willow Park, TX
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Strategic Clinical Research Group, LLC
mi
from
Willow Park, TX
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Mid Atlantic Retina - Wills Eye Hospital
mi
from
Cherry Hill, NJ
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Mid Atlantic Retina - Wills Eye Hospital
mi
from
Cherry Hill, NJ
Click here to add this to my saved trials
Clinical Assessment of a HYDRAGLYDE® Regimen
Clinical Assessment of a Regimen of AIR OPTIX® Plus HYDRAGLYDE® Silicone Hydrogel Lenses and HYDRAGLYDE® Containing Lens Care Solutions
Status: Enrolling
Updated:  12/31/1969
Alcon Investigative Site
mi
from
Birmingham, AL
Clinical Assessment of a HYDRAGLYDE® Regimen
Clinical Assessment of a Regimen of AIR OPTIX® Plus HYDRAGLYDE® Silicone Hydrogel Lenses and HYDRAGLYDE® Containing Lens Care Solutions
Status: Enrolling
Updated: 12/31/1969
Alcon Investigative Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Clinical Assessment of a HYDRAGLYDE® Regimen
Clinical Assessment of a Regimen of AIR OPTIX® Plus HYDRAGLYDE® Silicone Hydrogel Lenses and HYDRAGLYDE® Containing Lens Care Solutions
Status: Enrolling
Updated:  12/31/1969
Alcon Investigative Site
mi
from
Cleveland, OH
Clinical Assessment of a HYDRAGLYDE® Regimen
Clinical Assessment of a Regimen of AIR OPTIX® Plus HYDRAGLYDE® Silicone Hydrogel Lenses and HYDRAGLYDE® Containing Lens Care Solutions
Status: Enrolling
Updated: 12/31/1969
Alcon Investigative Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Clinical Assessment of a HYDRAGLYDE® Regimen
Clinical Assessment of a Regimen of AIR OPTIX® Plus HYDRAGLYDE® Silicone Hydrogel Lenses and HYDRAGLYDE® Containing Lens Care Solutions
Status: Enrolling
Updated:  12/31/1969
Alcon Investigative Site
mi
from
Columbus, OH
Clinical Assessment of a HYDRAGLYDE® Regimen
Clinical Assessment of a Regimen of AIR OPTIX® Plus HYDRAGLYDE® Silicone Hydrogel Lenses and HYDRAGLYDE® Containing Lens Care Solutions
Status: Enrolling
Updated: 12/31/1969
Alcon Investigative Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Clinical Assessment of a HYDRAGLYDE® Regimen
Clinical Assessment of a Regimen of AIR OPTIX® Plus HYDRAGLYDE® Silicone Hydrogel Lenses and HYDRAGLYDE® Containing Lens Care Solutions
Status: Enrolling
Updated:  12/31/1969
Alcon Investigative Site
mi
from
Memphis, TN
Clinical Assessment of a HYDRAGLYDE® Regimen
Clinical Assessment of a Regimen of AIR OPTIX® Plus HYDRAGLYDE® Silicone Hydrogel Lenses and HYDRAGLYDE® Containing Lens Care Solutions
Status: Enrolling
Updated: 12/31/1969
Alcon Investigative Site
mi
from
Memphis, TN
Click here to add this to my saved trials
Clinical Assessment of a HYDRAGLYDE® Regimen
Clinical Assessment of a Regimen of AIR OPTIX® Plus HYDRAGLYDE® Silicone Hydrogel Lenses and HYDRAGLYDE® Containing Lens Care Solutions
Status: Enrolling
Updated:  12/31/1969
Alcon Investigative Site
mi
from
Waterloo,
Clinical Assessment of a HYDRAGLYDE® Regimen
Clinical Assessment of a Regimen of AIR OPTIX® Plus HYDRAGLYDE® Silicone Hydrogel Lenses and HYDRAGLYDE® Containing Lens Care Solutions
Status: Enrolling
Updated: 12/31/1969
Alcon Investigative Site
mi
from
Waterloo,
Click here to add this to my saved trials
Clinical Assessment of a HYDRAGLYDE® Regimen
Clinical Assessment of a Regimen of AIR OPTIX® Plus HYDRAGLYDE® Silicone Hydrogel Lenses and HYDRAGLYDE® Containing Lens Care Solutions
Status: Enrolling
Updated:  12/31/1969
Alcon Investigative Site
mi
from
Houston, TX
Clinical Assessment of a HYDRAGLYDE® Regimen
Clinical Assessment of a Regimen of AIR OPTIX® Plus HYDRAGLYDE® Silicone Hydrogel Lenses and HYDRAGLYDE® Containing Lens Care Solutions
Status: Enrolling
Updated: 12/31/1969
Alcon Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Measurement of Anterior Chamber Cell Grading Using Ocular Coherence Tomography
Objective, Prospective Measurement of Anterior Chamber Cell Grading Using Anterior Chamber Ocular Coherence Tomography
Status: Enrolling
Updated:  12/31/1969
Doctors Office Center
mi
from
Newark, NJ
Measurement of Anterior Chamber Cell Grading Using Ocular Coherence Tomography
Objective, Prospective Measurement of Anterior Chamber Cell Grading Using Anterior Chamber Ocular Coherence Tomography
Status: Enrolling
Updated: 12/31/1969
Doctors Office Center
mi
from
Newark, NJ
Click here to add this to my saved trials
A Study of ADX-102 in Subjects With Allergic Conjunctivitis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Morrow, GA
A Study of ADX-102 in Subjects With Allergic Conjunctivitis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Morrow, GA
Click here to add this to my saved trials
A Study of ADX-102 in Subjects With Allergic Conjunctivitis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Mason, OH
A Study of ADX-102 in Subjects With Allergic Conjunctivitis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Mason, OH
Click here to add this to my saved trials
A Study of ADX-102 in Subjects With Allergic Conjunctivitis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of ADX-102 in Subjects With Allergic Conjunctivitis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of ADX-102 in Subjects With Allergic Conjunctivitis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Memphis, TN
A Study of ADX-102 in Subjects With Allergic Conjunctivitis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated:  12/31/1969
Golden Optometric Group
mi
from
Whittier, CA
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated: 12/31/1969
Golden Optometric Group
mi
from
Whittier, CA
Click here to add this to my saved trials
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated:  12/31/1969
Edward S. Wygonik, OD
mi
from
Jacksonville Beach, FL
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated: 12/31/1969
Edward S. Wygonik, OD
mi
from
Jacksonville Beach, FL
Click here to add this to my saved trials
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated:  12/31/1969
Dr. James Weber & Associates, PA
mi
from
Jacksonville, FL
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated: 12/31/1969
Dr. James Weber & Associates, PA
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated:  12/31/1969
Sabal Eye Care
mi
from
Longwood, FL
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated: 12/31/1969
Sabal Eye Care
mi
from
Longwood, FL
Click here to add this to my saved trials
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated:  12/31/1969
Maitland Vision Center
mi
from
Maitland, FL
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated: 12/31/1969
Maitland Vision Center
mi
from
Maitland, FL
Click here to add this to my saved trials
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated:  12/31/1969
Indiana University School of Optometry
mi
from
Bloomington, IN
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated: 12/31/1969
Indiana University School of Optometry
mi
from
Bloomington, IN
Click here to add this to my saved trials
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated:  12/31/1969
Kannarr Eye Care LLC
mi
from
Pittsburg, KA
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated: 12/31/1969
Kannarr Eye Care LLC
mi
from
Pittsburg, KA
Click here to add this to my saved trials
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated:  12/31/1969
ABQ Eye Care
mi
from
Albuquerque, NM
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated: 12/31/1969
ABQ Eye Care
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated:  12/31/1969
Sacco Eye Group
mi
from
Vestal, NY
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated: 12/31/1969
Sacco Eye Group
mi
from
Vestal, NY
Click here to add this to my saved trials
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated:  12/31/1969
ProCare Vision Centers
mi
from
Granville, OH
Evaluation of Astigmatic Contact Lenses
Evaluation of Astigmatic Contact Lenses
Status: Enrolling
Updated: 12/31/1969
ProCare Vision Centers
mi
from
Granville, OH
Click here to add this to my saved trials